Selective PDE4D inhibitor shows potential to treat Fragile X autism spectrum disorder

November 7, 2017, Tetra Discovery Partners

New preclinical research suggests the potential utility of BPN14770, a selective PDE4D inhibitor currently under development by Tetra Discovery Partners as a prospective treatment for memory and cognitive problems associated with Alzheimer's disease, in the treatment of Fragile X Syndrome (FXS) and possibly other autism spectrum disorders.

Daily treatment of adult male fmr1 C57B16 knockout (a standard FXS animal model) for 14 days reduced hyperarousal, and improved social interactions and increased natural behaviors such as nesting and marble burying compared to control FXS mice that received a placebo. At the same time, there was no deleterious effect on behavioral scores in normal wild-type mice treated with BPN14770. The behavioral benefits of BPN14770 in the FXS mice endured for two weeks after drug washout. Microscopic analysis of neurons in the prefrontal cortex from the treated FXS mice showed an improvement in dendritic spine morphology; this finding, combined with the 11 hour half-life of BPN14770 in mice, suggests that the enduring treatment benefits of BPN14770 were not due to slow washout of the drug.

The new research was published online today in Scientific Reports, an online, open-access primary research publication from the publishers of Nature by Tetra Discovery Partners and the company's research collaborators.

"This preclinical study strongly supports PDE4D as a therapeutic target for the treatment of FXS," said Mark E. Gurney, Ph.D., Chairman and Chief Executive Officer of Tetra Discovery Partners. "We have already demonstrated evidence of human safety and tolerability for BPN14770 in a Phase 1 study in healthy young and elderly volunteers. This research suggests BPN14770 may also have utility in the treatment of FXS, which is associated with a spectrum of neuropsychiatric symptoms, mild to severe cognitive impairment and intellectual disability, and potentially also find use in the treatment of other conditions on the autism spectrum."

"The results from these studies are very promising," commented Michael Tranfaglia, M.D., Medical Director and Chief Scientific Officer of the FRAXA Research Foundation. "Inhibition of PDE4 has been validated as a treatment strategy by many research groups in the Fragile X field. However, the current study demonstrates the enhanced therapeutic potential of PDE4D inhibition with BPN14770, which shows the ability to rescue major Fragile X phenotypes not only in acute dosing, but in chronic dosing as well.

"Furthermore, the significant carryover of BPN14770 effects, even two weeks after suggests this drug candidate has genuine long-term beneficial effects on Fragile X pathology," Dr. Tranfaglia continued. "Additionally, tolerance has been a major problem with other drug classes studied as potential treatments for Fragile X syndrome, such as mGluR5 NAMs and GABA-B agonists, but no tolerance was been seen in studies with BPN14770. The selective nature of this compound, which targets only PDE4D, also greatly improves the tolerability of the drug over past-studied, general PDE4 inhibitors, which should facilitate clinical trials in this difficult-to-treat population."

Explore further: New memory drug moves into Phase 1 clinical study

More information: Mark E. Gurney et al, Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D), Scientific Reports (2017). DOI: 10.1038/s41598-017-15028-x

Related Stories

New memory drug moves into Phase 1 clinical study

January 1, 2016
An experimental drug that may improve memory is now being tested in a Phase 1 safety trial. The compound, BPN14770, was developed by Tetra Discovery Partners, with support from the NIH Blueprint Neurotherapeutics Network, ...

Promise seen in possible treatment for autism spectrum disorder

November 1, 2017
Human chromosome 16p11.2 deletion syndrome is caused by the absence of about 27 genes on chromosome 16. This deletion is characterized by intellectual disability; impaired language, communication, and socialization skills; ...

Diabetes drug may help symptoms of autism associated condition

May 15, 2017
A widely used diabetes medication could help people with a common inherited form of autism, research shows.

Brain study reveals clues to treating Fragile X syndrome

August 3, 2017
Scientists have discovered how the brain can self-correct disruptions in processing, pointing the way towards possible new treatments for autism and intellectual disability.

Treatment window for Fragile X likely doesn't close after childhood

March 20, 2017
Brain samples from humans show that the treatment window for Fragile X syndrome likely remains open well into maturity after childhood, when previous tests with mice indicated it might close, according to a new Drexel University-led ...

New role for fragile X protein could offer clues for treatment

September 28, 2017
The protein behind fragile X syndrome acts as a genetic conductor, orchestrating a symphony of genes that help shape DNA's 3-D structure.

Recommended for you

Doctors fail to flag concussion patients for critical follow-up

May 25, 2018
As evidence builds of more long-term effects linked to concussion, a nationwide study led by scientists at UCSF and the University of Southern California has found that more than half of the patients seen at top-level trauma ...

New parts of the brain become active after students learn physics

May 24, 2018
Parts of the brain not traditionally associated with learning science become active when people are confronted with solving physics problems, a new study shows.

Study suggests brainwave link between disparate disorders

May 24, 2018
A brainwave abnormality could be a common link between Parkinson's disease, neuropathic pain, tinnitus and depression—a link that authors of a new study suggest could lead to treatment for all four conditions.

Bursts of brain activity linked to memory reactivation

May 24, 2018
Leading theories propose that sleep presents an opportune time for important, new memories to become stabilized. And it's long been known which brain waves are produced during sleep. But in a new study, researchers set out ...

Researchers define molecular basis to explain link between a pregnant mother's nutrition and infant growth

May 24, 2018
For years, pregnant mothers have questioned their nutritional habits: "Will eating more cause my baby to be overweight?" Or, "I'm eating for two, so it won't hurt to have an extra serving, right?"

Leg exercise is critical to brain and nervous system health

May 23, 2018
Groundbreaking research shows that neurological health depends as much on signals sent by the body's large, leg muscles to the brain as it does on directives from the brain to the muscles. Published today in Frontiers in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.